Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyArdeparin
Identification
- Name
- Ardeparin
- Accession Number
- DB00407 (APRD00803)
- Type
- Small Molecule
- Groups
- Approved, Investigational, Withdrawn
- Description
Ardeparin, marketed under the US trade name Normiflo, is a low molecular weight heparin (LMWH) anticoagulant used for the prevention of postoperative venous thrombosis. Ardeparin is derived via peroxide degradation of heparin extracted from porcine intestinal mucosa. Its molecular weight ranges from 2000 to 15,000 with an average molecular weight of 5500 to 6500. Normiflo was withdrawn from the US market in March 2000.
- Synonyms
- Not Available
- International/Other Brands
- Normiflo (Wyeth-Ayerst (United States))
- Categories
- UNII
- VL0L558GCB
- CAS number
- 9005-49-6
- Weight
- Not Available
- Chemical Formula
- Not Available
- InChI Key
- Not Available
- InChI
- Not Available
- IUPAC Name
- Not Available
- SMILES
- Not Available
Pharmacology
- Indication
For prevention of deep vein thrombosis, which may result in pulmonary embolism, following knee surgery.
- Pharmacodynamics
Ardeparin, an anticoagulant, is a fractionated heparin. It acts at multiple sites in the normal coagulation system to inhibit reactions that lead to the clotting of blood and the formation of fibrin clots both in vitro and in vivo.
- Mechanism of action
Ardeparin binds to antithrombin III, accelerating its activity in inactivating factor Xa and thrombin, thereby inhibiting thrombosis. Ardeparin also binds to heparin cofactor II, inhibiting thrombin. Ardeparin does not effect prothrombin time (PT) assays and may prolong activated partial thromboplastin time (APTT). Ardeparin has double the anti-factor Xa activity versus anti-factor IIa activity, compared to unfractionated heparin which has approximately equal anti-factor Xa activity and anti-factor IIa activity.
Target Actions Organism AAntithrombin-III potentiatorHuman AHeparin cofactor 2 agonistHuman - Absorption
Well absorbed following subcutaneous administration, with a mean bioavailability of 92% (based on anti-factor Xa activity).
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
Liver and the reticulo-endothelial system are the sites of biotransformation.
- Route of elimination
- Not Available
- Half life
Elimination half-life for anti-factor Xa activity averages 3.3 hours following a single intravenous dose, while elimination half-life for anti-factor IIa activity averages 1.2 hours following a single intravenous dose.
- Clearance
- Not Available
- Toxicity
Symptoms of overdose may include excessive bleeding and bruising.
- Affected organisms
- Humans and other mammals
- Pathways
Pathway Category Enoxaparin Action Pathway Drug action Ardeparin Action Pathway Drug action Ardeparin Action Pathway Drug action Enoxaparin Action Pathway Drug action - Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group (4R)-limonene (4R)-limonene may increase the anticoagulant activities of Ardeparin. Investigational Abciximab Abciximab may increase the anticoagulant activities of Ardeparin. Approved Aceclofenac Aceclofenac may increase the anticoagulant activities of Ardeparin. Approved, Investigational Acemetacin The risk or severity of bleeding can be increased when Ardeparin is combined with Acemetacin. Approved, Experimental, Investigational Acenocoumarol Ardeparin may increase the anticoagulant activities of Acenocoumarol. Approved, Investigational Acetylsalicylic acid Acetylsalicylic acid may increase the anticoagulant activities of Ardeparin. Approved, Vet Approved Adapalene Adapalene may increase the anticoagulant activities of Ardeparin. Approved Alclofenac Alclofenac may increase the anticoagulant activities of Ardeparin. Approved, Withdrawn Aliskiren Ardeparin may increase the hyperkalemic activities of Aliskiren. Approved, Investigational Allylestrenol The therapeutic efficacy of Ardeparin can be decreased when used in combination with Allylestrenol. Approved Alminoprofen Alminoprofen may increase the anticoagulant activities of Ardeparin. Experimental Aloxiprin Aloxiprin may increase the anticoagulant activities of Ardeparin. Experimental Alprostadil Alprostadil may increase the anticoagulant activities of Ardeparin. Approved, Investigational Alteplase Alteplase may increase the anticoagulant activities of Ardeparin. Approved Altrenogest The therapeutic efficacy of Ardeparin can be decreased when used in combination with Altrenogest. Vet Approved Amikacin The therapeutic efficacy of Amikacin can be decreased when used in combination with Ardeparin. Approved, Investigational, Vet Approved Amiloride Ardeparin may increase the hyperkalemic activities of Amiloride. Approved Aminosalicylic Acid Aminosalicylic Acid may increase the anticoagulant activities of Ardeparin. Approved Anagrelide Anagrelide may increase the anticoagulant activities of Ardeparin. Approved Ancrod Ardeparin may increase the anticoagulant activities of Ancrod. Approved, Investigational Andrographolide Andrographolide may increase the anticoagulant activities of Ardeparin. Investigational Anisodamine Anisodamine may increase the anticoagulant activities of Ardeparin. Investigational Anistreplase Anistreplase may increase the anticoagulant activities of Ardeparin. Approved Antipyrine Antipyrine may increase the anticoagulant activities of Ardeparin. Approved, Investigational Antithrombin III human Ardeparin may increase the anticoagulant activities of Antithrombin III human. Approved Apixaban Apixaban may increase the anticoagulant activities of Ardeparin. Approved Apocynin Apocynin may increase the anticoagulant activities of Ardeparin. Investigational Apremilast Apremilast may increase the anticoagulant activities of Ardeparin. Approved, Investigational Aprotinin The therapeutic efficacy of Ardeparin can be decreased when used in combination with Aprotinin. Approved, Investigational, Withdrawn Argatroban Argatroban may increase the anticoagulant activities of Ardeparin. Approved, Investigational Astaxanthin Astaxanthin may increase the anticoagulant activities of Ardeparin. Investigational Azapropazone Azapropazone may increase the anticoagulant activities of Ardeparin. Withdrawn Azelastine Azelastine may increase the anticoagulant activities of Ardeparin. Approved Azficel-T The risk or severity of adverse effects can be increased when Ardeparin is combined with Azficel-T. Approved, Investigational Azilsartan medoxomil Ardeparin may increase the hyperkalemic activities of Azilsartan medoxomil. Approved, Investigational Balsalazide Balsalazide may increase the anticoagulant activities of Ardeparin. Approved, Investigational Batroxobin Batroxobin may increase the anticoagulant activities of Ardeparin. Experimental Bazedoxifene Bazedoxifene may decrease the anticoagulant activities of Ardeparin. Approved, Investigational Becaplermin Becaplermin may increase the anticoagulant activities of Ardeparin. Approved, Investigational Bemiparin Bemiparin may increase the anticoagulant activities of Ardeparin. Approved, Investigational Bendazac Bendazac may increase the anticoagulant activities of Ardeparin. Experimental Benorilate Benorilate may increase the anticoagulant activities of Ardeparin. Experimental Benoxaprofen Benoxaprofen may increase the anticoagulant activities of Ardeparin. Withdrawn Benzydamine Benzydamine may increase the anticoagulant activities of Ardeparin. Approved Beraprost Beraprost may increase the anticoagulant activities of Ardeparin. Investigational Bevonium Bevonium may increase the anticoagulant activities of Ardeparin. Experimental Bivalirudin Bivalirudin may increase the anticoagulant activities of Ardeparin. Approved, Investigational Brinase Brinase may increase the anticoagulant activities of Ardeparin. Experimental Bromfenac Bromfenac may increase the anticoagulant activities of Ardeparin. Approved Bucillamine Bucillamine may increase the anticoagulant activities of Ardeparin. Investigational Bufexamac Bufexamac may increase the anticoagulant activities of Ardeparin. Approved, Experimental Buflomedil Buflomedil may increase the anticoagulant activities of Ardeparin. Experimental Bumadizone Bumadizone may increase the anticoagulant activities of Ardeparin. Experimental Butylphthalide Butylphthalide may increase the anticoagulant activities of Ardeparin. Investigational Canagliflozin Ardeparin may increase the hyperkalemic activities of Canagliflozin. Approved Candesartan Ardeparin may increase the hyperkalemic activities of Candesartan. Experimental Candesartan cilexetil Ardeparin may increase the hyperkalemic activities of Candesartan cilexetil. Approved Cangrelor Cangrelor may increase the anticoagulant activities of Ardeparin. Approved Caplacizumab Caplacizumab may increase the anticoagulant activities of Ardeparin. Investigational Carbaspirin calcium Carbaspirin calcium may increase the anticoagulant activities of Ardeparin. Experimental, Investigational Carprofen Carprofen may increase the anticoagulant activities of Ardeparin. Approved, Vet Approved, Withdrawn Carvedilol The risk or severity of hyperkalemia can be increased when Ardeparin is combined with Carvedilol. Approved, Investigational Castanospermine Castanospermine may increase the anticoagulant activities of Ardeparin. Experimental Celecoxib Celecoxib may increase the anticoagulant activities of Ardeparin. Approved, Investigational Certoparin Ardeparin may increase the anticoagulant activities of Certoparin. Approved, Investigational Chlormadinone The therapeutic efficacy of Ardeparin can be decreased when used in combination with Chlormadinone. Experimental Chloroquine Chloroquine may increase the anticoagulant activities of Ardeparin. Approved, Investigational, Vet Approved Chlorotrianisene Chlorotrianisene may decrease the anticoagulant activities of Ardeparin. Investigational, Withdrawn Choline magnesium trisalicylate Choline magnesium trisalicylate may increase the anticoagulant activities of Ardeparin. Approved Cilostazol Cilostazol may increase the anticoagulant activities of Ardeparin. Approved, Investigational Clonixin Clonixin may increase the anticoagulant activities of Ardeparin. Approved Clopidogrel Clopidogrel may increase the anticoagulant activities of Ardeparin. Approved Cloricromen Cloricromen may increase the anticoagulant activities of Ardeparin. Experimental Clorindione Clorindione may increase the anticoagulant activities of Ardeparin. Experimental Collagenase clostridium histolyticum The risk or severity of adverse effects can be increased when Ardeparin is combined with Collagenase clostridium histolyticum. Approved, Investigational Conjugated estrogens Conjugated estrogens may decrease the anticoagulant activities of Ardeparin. Approved Curcumin Curcumin may increase the anticoagulant activities of Ardeparin. Approved, Investigational Cyclosporine The risk or severity of hyperkalemia can be increased when Ardeparin is combined with Cyclosporine. Approved, Investigational, Vet Approved Dabigatran etexilate Dabigatran etexilate may increase the anticoagulant activities of Ardeparin. Approved Daidzein Daidzein may decrease the anticoagulant activities of Ardeparin. Experimental Dalteparin Ardeparin may increase the anticoagulant activities of Dalteparin. Approved Danaparoid Ardeparin may increase the anticoagulant activities of Danaparoid. Approved, Withdrawn Darexaban Ardeparin may increase the anticoagulant activities of Darexaban. Investigational Dasatinib Dasatinib may increase the anticoagulant activities of Ardeparin. Approved, Investigational Deferasirox The risk or severity of adverse effects can be increased when Ardeparin is combined with Deferasirox. Approved, Investigational Demegestone The therapeutic efficacy of Ardeparin can be decreased when used in combination with Demegestone. Approved Deoxycholic Acid The risk or severity of adverse effects can be increased when Ardeparin is combined with Deoxycholic Acid. Approved Dersalazine Dersalazine may increase the anticoagulant activities of Ardeparin. Investigational Desirudin Ardeparin may increase the anticoagulant activities of Desirudin. Approved Desmoteplase Desmoteplase may increase the anticoagulant activities of Ardeparin. Investigational Desogestrel The therapeutic efficacy of Ardeparin can be decreased when used in combination with Desogestrel. Approved Desvenlafaxine Desvenlafaxine may increase the antiplatelet activities of Ardeparin. Approved, Investigational Dextran Ardeparin may increase the anticoagulant activities of Dextran. Approved, Investigational, Vet Approved Diclofenac The risk or severity of bleeding and hemorrhage can be increased when Diclofenac is combined with Ardeparin. Approved, Vet Approved Dicoumarol Dicoumarol may increase the anticoagulant activities of Ardeparin. Approved Dienestrol Dienestrol may decrease the anticoagulant activities of Ardeparin. Approved, Investigational Dienogest The therapeutic efficacy of Ardeparin can be decreased when used in combination with Dienogest. Approved Diethylstilbestrol Diethylstilbestrol may decrease the anticoagulant activities of Ardeparin. Approved, Investigational Difenpiramide Difenpiramide may increase the anticoagulant activities of Ardeparin. Experimental Diflunisal Diflunisal may increase the anticoagulant activities of Ardeparin. Approved, Investigational Diphenadione Diphenadione may increase the anticoagulant activities of Ardeparin. Experimental Dipyridamole Dipyridamole may increase the anticoagulant activities of Ardeparin. Approved Ditazole Ditazole may increase the anticoagulant activities of Ardeparin. Approved, Withdrawn Drospirenone The therapeutic efficacy of Ardeparin can be decreased when used in combination with Drospirenone. Approved Drotrecogin alfa Drotrecogin alfa may increase the anticoagulant activities of Ardeparin. Approved, Investigational, Withdrawn Droxicam Droxicam may increase the anticoagulant activities of Ardeparin. Withdrawn Duvelisib Duvelisib may increase the anticoagulant activities of Ardeparin. Investigational Dydrogesterone The therapeutic efficacy of Ardeparin can be decreased when used in combination with Dydrogesterone. Approved, Investigational, Withdrawn E-6201 E-6201 may increase the anticoagulant activities of Ardeparin. Investigational Edetic Acid Ardeparin may increase the anticoagulant activities of Edetic Acid. Approved, Vet Approved Edoxaban Edoxaban may increase the anticoagulant activities of Ardeparin. Approved Enoxaparin Ardeparin may increase the anticoagulant activities of Enoxaparin. Approved Epimestrol Epimestrol may decrease the anticoagulant activities of Ardeparin. Experimental Epinastine Epinastine may increase the anticoagulant activities of Ardeparin. Approved, Investigational Epirizole Epirizole may increase the anticoagulant activities of Ardeparin. Approved Eplerenone Ardeparin may increase the hyperkalemic activities of Eplerenone. Approved Eplivanserin Eplivanserin may increase the anticoagulant activities of Ardeparin. Investigational Epoprostenol Epoprostenol may increase the anticoagulant activities of Ardeparin. Approved Eprosartan Ardeparin may increase the hyperkalemic activities of Eprosartan. Approved Eptifibatide Eptifibatide may increase the anticoagulant activities of Ardeparin. Approved, Investigational Equol Equol may decrease the anticoagulant activities of Ardeparin. Investigational Estradiol Estradiol may decrease the anticoagulant activities of Ardeparin. Approved, Investigational, Vet Approved Estradiol acetate Estradiol acetate may decrease the anticoagulant activities of Ardeparin. Approved, Investigational, Vet Approved Estradiol cypionate Estradiol cypionate may decrease the anticoagulant activities of Ardeparin. Approved, Investigational, Vet Approved Estradiol valerate Estradiol valerate may decrease the anticoagulant activities of Ardeparin. Approved, Investigational, Vet Approved Estriol Estriol may decrease the anticoagulant activities of Ardeparin. Approved, Investigational, Vet Approved Estrogens, esterified Estrogens, esterified may decrease the anticoagulant activities of Ardeparin. Approved Estrone Estrone may decrease the anticoagulant activities of Ardeparin. Approved Etanercept Etanercept may increase the anticoagulant activities of Ardeparin. Approved, Investigational Ethenzamide Ethenzamide may increase the anticoagulant activities of Ardeparin. Experimental Ethinyl Estradiol Ethinyl Estradiol may decrease the anticoagulant activities of Ardeparin. Approved Ethyl biscoumacetate Ardeparin may increase the anticoagulant activities of Ethyl biscoumacetate. Withdrawn Ethynodiol The therapeutic efficacy of Ardeparin can be decreased when used in combination with Ethynodiol. Experimental Etodolac Etodolac may increase the anticoagulant activities of Ardeparin. Approved, Investigational, Vet Approved Etofenamate Etofenamate may increase the anticoagulant activities of Ardeparin. Approved, Investigational Etonogestrel The therapeutic efficacy of Ardeparin can be decreased when used in combination with Etonogestrel. Approved, Investigational Etoricoxib Etoricoxib may increase the anticoagulant activities of Ardeparin. Approved, Investigational Evening primrose oil Evening primrose oil may increase the anticoagulant activities of Ardeparin. Investigational, Nutraceutical Exisulind Exisulind may increase the anticoagulant activities of Ardeparin. Investigational Felbinac Felbinac may increase the anticoagulant activities of Ardeparin. Experimental Fenbufen Fenbufen may increase the anticoagulant activities of Ardeparin. Approved Fenoprofen Fenoprofen may increase the anticoagulant activities of Ardeparin. Approved Fentiazac Fentiazac may increase the anticoagulant activities of Ardeparin. Experimental Feprazone Feprazone may increase the anticoagulant activities of Ardeparin. Experimental Ferulic acid Ferulic acid may increase the anticoagulant activities of Ardeparin. Experimental Fibrinolysin Fibrinolysin may increase the anticoagulant activities of Ardeparin. Investigational Fimasartan Ardeparin may increase the hyperkalemic activities of Fimasartan. Approved, Investigational Floctafenine Floctafenine may increase the anticoagulant activities of Ardeparin. Approved, Withdrawn Fluindione Ardeparin may increase the anticoagulant activities of Fluindione. Approved, Investigational Flunixin Flunixin may increase the anticoagulant activities of Ardeparin. Vet Approved Flunoxaprofen Flunoxaprofen may increase the anticoagulant activities of Ardeparin. Experimental Fluoxetine Fluoxetine may increase the antiplatelet activities of Ardeparin. Approved, Vet Approved Flurbiprofen Flurbiprofen may increase the anticoagulant activities of Ardeparin. Approved, Investigational Fluvoxamine Fluvoxamine may increase the antiplatelet activities of Ardeparin. Approved, Investigational Fondaparinux Ardeparin may increase the anticoagulant activities of Fondaparinux sodium. Approved, Investigational Forasartan Ardeparin may increase the hyperkalemic activities of Forasartan. Experimental Fosinopril The risk or severity of hyperkalemia can be increased when Ardeparin is combined with Fosinopril. Approved Gabexate Ardeparin may increase the anticoagulant activities of Gabexate. Investigational Genistein Genistein may decrease the anticoagulant activities of Ardeparin. Investigational Gestodene The therapeutic efficacy of Ardeparin can be decreased when used in combination with Gestodene. Approved, Investigational Gestonorone The therapeutic efficacy of Ardeparin can be decreased when used in combination with Gestonorone. Experimental Gestrinone The therapeutic efficacy of Ardeparin can be decreased when used in combination with Gestrinone. Approved Guacetisal Guacetisal may increase the anticoagulant activities of Ardeparin. Experimental Hemin Hemin may increase the anticoagulant activities of Ardeparin. Approved, Investigational Hemoglobin crosfumaril Hemoglobin crosfumaril may increase the anticoagulant activities of Ardeparin. Experimental Heparin Ardeparin may increase the anticoagulant activities of Heparin. Approved, Investigational Hexestrol Hexestrol may decrease the anticoagulant activities of Ardeparin. Withdrawn Higenamine Higenamine may increase the anticoagulant activities of Ardeparin. Investigational Hydroxyprogesterone caproate The therapeutic efficacy of Ardeparin can be decreased when used in combination with Hydroxyprogesterone caproate. Approved, Investigational Hydroxytyrosol Hydroxytyrosol may increase the anticoagulant activities of Ardeparin. Investigational Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Ardeparin is combined with Ibritumomab tiuxetan. Approved, Investigational Ibrutinib The risk or severity of adverse effects can be increased when Ibrutinib is combined with Ardeparin. Approved Ibudilast Ibudilast may increase the anticoagulant activities of Ardeparin. Approved, Investigational Ibuprofen The risk or severity of bleeding and hemorrhage can be increased when Ibuprofen is combined with Ardeparin. Approved Ibuproxam Ibuproxam may increase the anticoagulant activities of Ardeparin. Withdrawn Icatibant Icatibant may increase the anticoagulant activities of Ardeparin. Approved, Investigational Icosapent ethyl Icosapent ethyl may increase the anticoagulant activities of Ardeparin. Approved, Investigational, Nutraceutical Idraparinux Ardeparin may increase the anticoagulant activities of Idraparinux. Investigational Ifenprodil Ifenprodil may increase the anticoagulant activities of Ardeparin. Approved, Investigational, Withdrawn Ifetroban Ifetroban may increase the anticoagulant activities of Ardeparin. Investigational Iloprost Iloprost may increase the anticoagulant activities of Ardeparin. Approved, Investigational Imidazole salicylate Imidazole salicylate may increase the anticoagulant activities of Ardeparin. Experimental Indobufen Indobufen may increase the anticoagulant activities of Ardeparin. Investigational Indomethacin Indomethacin may increase the anticoagulant activities of Ardeparin. Approved, Investigational Indoprofen Indoprofen may increase the anticoagulant activities of Ardeparin. Withdrawn Irbesartan Ardeparin may increase the hyperkalemic activities of Irbesartan. Approved, Investigational Isoxicam Isoxicam may increase the anticoagulant activities of Ardeparin. Withdrawn Kebuzone Kebuzone may increase the anticoagulant activities of Ardeparin. Experimental Ketanserin Ketanserin may increase the anticoagulant activities of Ardeparin. Investigational Ketoprofen Ketoprofen may increase the anticoagulant activities of Ardeparin. Approved, Vet Approved Ketorolac The risk or severity of bleeding and hemorrhage can be increased when Ketorolac is combined with Ardeparin. Approved Labetalol The risk or severity of hyperkalemia can be increased when Ardeparin is combined with Labetalol. Approved Leflunomide Leflunomide may increase the anticoagulant activities of Ardeparin. Approved, Investigational Lepirudin Ardeparin may increase the anticoagulant activities of Lepirudin. Approved Letaxaban Ardeparin may increase the anticoagulant activities of Letaxaban. Investigational Levonorgestrel Levonorgestrel may decrease the anticoagulant activities of Ardeparin. Approved, Investigational Limaprost The risk or severity of adverse effects can be increased when Limaprost is combined with Ardeparin. Approved, Investigational Linsidomine Linsidomine may increase the anticoagulant activities of Ardeparin. Experimental Lisofylline Lisofylline may increase the anticoagulant activities of Ardeparin. Investigational Lonazolac Lonazolac may increase the anticoagulant activities of Ardeparin. Experimental Lornoxicam Lornoxicam may increase the anticoagulant activities of Ardeparin. Approved, Investigational Losartan The risk or severity of hyperkalemia can be increased when Ardeparin is combined with Losartan. Approved Loxoprofen Loxoprofen may increase the anticoagulant activities of Ardeparin. Approved, Investigational Lumiracoxib Lumiracoxib may increase the anticoagulant activities of Ardeparin. Approved, Investigational Lynestrenol The therapeutic efficacy of Ardeparin can be decreased when used in combination with Lynestrenol. Approved, Investigational Magnesium salicylate Magnesium salicylate may increase the anticoagulant activities of Ardeparin. Approved Masoprocol Masoprocol may increase the anticoagulant activities of Ardeparin. Approved, Investigational Meclofenamic acid Meclofenamic acid may increase the anticoagulant activities of Ardeparin. Approved, Vet Approved Medrogestone The therapeutic efficacy of Ardeparin can be decreased when used in combination with Medrogestone. Approved Medroxyprogesterone acetate The therapeutic efficacy of Ardeparin can be decreased when used in combination with Medroxyprogesterone acetate. Approved, Investigational Mefenamic acid Mefenamic acid may increase the anticoagulant activities of Ardeparin. Approved Megestrol acetate The therapeutic efficacy of Ardeparin can be decreased when used in combination with Megestrol acetate. Approved, Investigational, Vet Approved Melagatran Ardeparin may increase the anticoagulant activities of Melagatran. Experimental Meloxicam Meloxicam may increase the anticoagulant activities of Ardeparin. Approved, Vet Approved Mesalazine Mesalazine may increase the anticoagulant activities of Ardeparin. Approved Mestranol Mestranol may decrease the anticoagulant activities of Ardeparin. Approved Metamizole Metamizole may increase the anticoagulant activities of Ardeparin. Approved, Investigational, Withdrawn Methallenestril Methallenestril may decrease the anticoagulant activities of Ardeparin. Experimental Methyl salicylate The risk or severity of bleeding can be increased when Methyl salicylate is combined with Ardeparin. Approved, Vet Approved Methylestrenolone The therapeutic efficacy of Ardeparin can be decreased when used in combination with Methylestrenolone. Experimental Metoprolol The risk or severity of hyperkalemia can be increased when Ardeparin is combined with Metoprolol. Approved, Investigational Milrinone Milrinone may increase the anticoagulant activities of Ardeparin. Approved Mizoribine Mizoribine may increase the anticoagulant activities of Ardeparin. Investigational Mofebutazone Mofebutazone may increase the anticoagulant activities of Ardeparin. Experimental Moxestrol Moxestrol may decrease the anticoagulant activities of Ardeparin. Experimental Mycophenolate mofetil Mycophenolate mofetil may increase the anticoagulant activities of Ardeparin. Approved, Investigational Mycophenolic acid Mycophenolic acid may increase the anticoagulant activities of Ardeparin. Approved Nabumetone Nabumetone may increase the anticoagulant activities of Ardeparin. Approved Nadroparin Ardeparin may increase the anticoagulant activities of Nadroparin. Approved, Investigational Nafamostat Nafamostat may increase the anticoagulant activities of Ardeparin. Approved, Investigational Naftifine Naftifine may increase the anticoagulant activities of Ardeparin. Approved Naftopidil The risk or severity of bleeding can be increased when Naftopidil is combined with Ardeparin. Investigational Naproxen The risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Ardeparin. Approved, Vet Approved Neomycin The therapeutic efficacy of Neomycin can be decreased when used in combination with Ardeparin. Approved, Vet Approved Nepafenac Nepafenac may increase the anticoagulant activities of Ardeparin. Approved, Investigational Nifenazone Nifenazone may increase the anticoagulant activities of Ardeparin. Experimental Niflumic Acid Niflumic Acid may increase the anticoagulant activities of Ardeparin. Approved Nimesulide The risk or severity of bleeding and hemorrhage can be increased when Nimesulide is combined with Ardeparin. Approved, Investigational, Withdrawn Nintedanib The risk or severity of adverse effects can be increased when Ardeparin is combined with Nintedanib. Approved Nitroaspirin Nitroaspirin may increase the anticoagulant activities of Ardeparin. Investigational Nomegestrol The therapeutic efficacy of Ardeparin can be decreased when used in combination with Nomegestrol. Approved Norethisterone The therapeutic efficacy of Ardeparin can be decreased when used in combination with Norethisterone. Approved Norgestrienone The therapeutic efficacy of Ardeparin can be decreased when used in combination with Norgestrienone. Experimental Obinutuzumab The risk or severity of adverse effects can be increased when Ardeparin is combined with Obinutuzumab. Approved, Investigational Olmesartan Ardeparin may increase the hyperkalemic activities of Olmesartan. Approved, Investigational Olopatadine Olopatadine may increase the anticoagulant activities of Ardeparin. Approved Olsalazine Olsalazine may increase the anticoagulant activities of Ardeparin. Approved Omacetaxine mepesuccinate The risk or severity of bleeding can be increased when Ardeparin is combined with Omacetaxine mepesuccinate. Approved, Investigational Omega-3 fatty acids Omega-3 fatty acids may increase the anticoagulant activities of Ardeparin. Approved, Nutraceutical Omega-3-carboxylic acids The therapeutic efficacy of Ardeparin can be increased when used in combination with Omega-3-carboxylic acids. Approved, Investigational Orgotein Orgotein may increase the anticoagulant activities of Ardeparin. Vet Approved Otamixaban Ardeparin may increase the anticoagulant activities of Otamixaban. Investigational Oxaprozin Oxaprozin may increase the anticoagulant activities of Ardeparin. Approved Oxyphenbutazone Oxyphenbutazone may increase the anticoagulant activities of Ardeparin. Approved, Withdrawn Ozagrel Ozagrel may increase the anticoagulant activities of Ardeparin. Investigational Palifermin The serum concentration of Palifermin can be increased when it is combined with Ardeparin. Approved Palmidrol Palmidrol may increase the anticoagulant activities of Ardeparin. Experimental, Nutraceutical Parecoxib Parecoxib may increase the anticoagulant activities of Ardeparin. Approved Parnaparin Parnaparin may increase the anticoagulant activities of Ardeparin. Approved, Investigational Paromomycin The therapeutic efficacy of Paromomycin can be decreased when used in combination with Ardeparin. Approved, Investigational Paroxetine Paroxetine may increase the antiplatelet activities of Ardeparin. Approved, Investigational Parthenolide Parthenolide may increase the anticoagulant activities of Ardeparin. Approved, Investigational Pentaerythritol Tetranitrate Ardeparin may increase the anticoagulant activities of Pentaerythritol Tetranitrate. Approved Pentosan Polysulfate Pentosan Polysulfate may increase the anticoagulant activities of Ardeparin. Approved Pentoxifylline Pentoxifylline may increase the anticoagulant activities of Ardeparin. Approved, Investigational Phenindione Ardeparin may increase the anticoagulant activities of Phenindione. Approved, Investigational Phenprocoumon Ardeparin may increase the anticoagulant activities of Phenprocoumon. Approved, Investigational Phenyl aminosalicylate Phenyl aminosalicylate may increase the anticoagulant activities of Ardeparin. Approved Phenylbutazone Phenylbutazone may increase the anticoagulant activities of Ardeparin. Approved, Vet Approved Picotamide Picotamide may increase the anticoagulant activities of Ardeparin. Experimental Pimecrolimus Pimecrolimus may increase the anticoagulant activities of Ardeparin. Approved, Investigational Pirfenidone Pirfenidone may increase the anticoagulant activities of Ardeparin. Approved, Investigational Piroxicam Piroxicam may increase the anticoagulant activities of Ardeparin. Approved, Investigational Pirprofen Pirprofen may increase the anticoagulant activities of Ardeparin. Experimental Polyestradiol phosphate Polyestradiol phosphate may decrease the anticoagulant activities of Ardeparin. Approved Potassium Chloride The risk or severity of hyperkalemia can be increased when Potassium Chloride is combined with Ardeparin. Approved, Withdrawn Potassium Citrate Ardeparin may increase the anticoagulant activities of Potassium Citrate. Approved, Investigational, Vet Approved Pranoprofen Pranoprofen may increase the anticoagulant activities of Ardeparin. Experimental, Investigational Prasugrel Prasugrel may increase the anticoagulant activities of Ardeparin. Approved Progesterone The therapeutic efficacy of Ardeparin can be decreased when used in combination with Progesterone. Approved, Vet Approved Proglumetacin Proglumetacin may increase the anticoagulant activities of Ardeparin. Experimental Promegestone The therapeutic efficacy of Ardeparin can be decreased when used in combination with Promegestone. Experimental Promestriene Promestriene may decrease the anticoagulant activities of Ardeparin. Investigational Propacetamol Propacetamol may increase the anticoagulant activities of Ardeparin. Approved, Investigational Propafenone The risk or severity of hyperkalemia can be increased when Ardeparin is combined with Propafenone. Approved Propranolol The risk or severity of hyperkalemia can be increased when Ardeparin is combined with Propranolol. Approved, Investigational Propyphenazone Propyphenazone may increase the anticoagulant activities of Ardeparin. Experimental Proquazone Proquazone may increase the anticoagulant activities of Ardeparin. Experimental Protein C Ardeparin may increase the anticoagulant activities of Protein C. Approved Protein S human Ardeparin may increase the anticoagulant activities of Protein S human. Approved Protocatechualdehyde Ardeparin may increase the anticoagulant activities of Protocatechualdehyde. Approved PTC299 PTC299 may increase the anticoagulant activities of Ardeparin. Investigational Quinestrol Quinestrol may decrease the anticoagulant activities of Ardeparin. Approved Quingestanol The therapeutic efficacy of Ardeparin can be decreased when used in combination with Quingestanol. Experimental Ramatroban Ramatroban may increase the anticoagulant activities of Ardeparin. Investigational Relcovaptan Relcovaptan may increase the anticoagulant activities of Ardeparin. Investigational Resveratrol Resveratrol may increase the anticoagulant activities of Ardeparin. Approved, Experimental, Investigational Reteplase Reteplase may increase the anticoagulant activities of Ardeparin. Approved, Investigational Reviparin Ardeparin may increase the anticoagulant activities of Reviparin. Approved, Investigational Ridogrel Ridogrel may increase the anticoagulant activities of Ardeparin. Approved Rivaroxaban Ardeparin may increase the anticoagulant activities of Rivaroxaban. Approved Rofecoxib Rofecoxib may increase the anticoagulant activities of Ardeparin. Approved, Investigational, Withdrawn Sacubitril Ardeparin may increase the hyperkalemic activities of Sacubitril. Approved Salicylamide Salicylamide may increase the anticoagulant activities of Ardeparin. Approved Salicylic acid The risk or severity of bleeding can be increased when Salicylic acid is combined with Ardeparin. Approved, Investigational, Vet Approved Salsalate Salsalate may increase the anticoagulant activities of Ardeparin. Approved Saprisartan Ardeparin may increase the hyperkalemic activities of Saprisartan. Experimental Saralasin Ardeparin may increase the hyperkalemic activities of Saralasin. Investigational Sarpogrelate Sarpogrelate may increase the anticoagulant activities of Ardeparin. Investigational Saruplase Saruplase may increase the anticoagulant activities of Ardeparin. Experimental Secoisolariciresinol Secoisolariciresinol may decrease the anticoagulant activities of Ardeparin. Investigational Semapimod Semapimod may increase the anticoagulant activities of Ardeparin. Investigational Seratrodast Seratrodast may increase the anticoagulant activities of Ardeparin. Approved Serrapeptase Serrapeptase may increase the anticoagulant activities of Ardeparin. Investigational Sevoflurane Sevoflurane may increase the anticoagulant activities of Ardeparin. Approved, Vet Approved Sodium Citrate Ardeparin may increase the anticoagulant activities of Sodium Citrate. Approved, Investigational Spironolactone The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Ardeparin. Approved SRT501 SRT501 may increase the anticoagulant activities of Ardeparin. Investigational Sugammadex Sugammadex may increase the anticoagulant activities of Ardeparin. Approved Sulfasalazine The risk or severity of bleeding can be increased when Sulfasalazine is combined with Ardeparin. Approved Sulindac The risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Ardeparin. Approved, Investigational Sulodexide Ardeparin may increase the anticoagulant activities of Sulodexide. Approved, Investigational Suprofen Suprofen may increase the anticoagulant activities of Ardeparin. Approved, Withdrawn Suxibuzone Suxibuzone may increase the anticoagulant activities of Ardeparin. Experimental Synthetic Conjugated Estrogens, A Synthetic Conjugated Estrogens, A may decrease the anticoagulant activities of Ardeparin. Approved Synthetic Conjugated Estrogens, B Synthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Ardeparin. Approved Tarenflurbil Tarenflurbil may increase the anticoagulant activities of Ardeparin. Investigational Tasosartan Ardeparin may increase the hyperkalemic activities of Tasosartan. Approved Telmisartan Ardeparin may increase the hyperkalemic activities of Telmisartan. Approved, Investigational Tenecteplase Tenecteplase may increase the anticoagulant activities of Ardeparin. Approved Tenidap Tenidap may increase the anticoagulant activities of Ardeparin. Experimental Tenoxicam Tenoxicam may increase the anticoagulant activities of Ardeparin. Approved Tepoxalin Tepoxalin may increase the anticoagulant activities of Ardeparin. Vet Approved Teriflunomide Teriflunomide may increase the anticoagulant activities of Ardeparin. Approved Tesmilifene Tesmilifene may increase the anticoagulant activities of Ardeparin. Investigational Testosterone cypionate The therapeutic efficacy of Ardeparin can be increased when used in combination with Testosterone cypionate. Approved Testosterone enanthate The therapeutic efficacy of Ardeparin can be increased when used in combination with Testosterone enanthate. Approved Testosterone undecanoate The therapeutic efficacy of Ardeparin can be increased when used in combination with Testosterone undecanoate. Approved, Investigational Tiaprofenic acid Tiaprofenic acid may increase the anticoagulant activities of Ardeparin. Approved Tibolone Tibolone may increase the anticoagulant activities of Ardeparin. Approved, Investigational Ticagrelor Ticagrelor may increase the anticoagulant activities of Ardeparin. Approved Ticlopidine Ticlopidine may increase the anticoagulant activities of Ardeparin. Approved Tinoridine Tinoridine may increase the anticoagulant activities of Ardeparin. Investigational Tioclomarol Tioclomarol may increase the anticoagulant activities of Ardeparin. Experimental Tipranavir Tipranavir may increase the anticoagulant activities of Ardeparin. Approved, Investigational Tirofiban Tirofiban may increase the anticoagulant activities of Ardeparin. Approved Tolfenamic Acid The risk or severity of bleeding and hemorrhage can be increased when Tolfenamic Acid is combined with Ardeparin. Approved, Investigational Tolmetin Tolmetin may increase the anticoagulant activities of Ardeparin. Approved Tositumomab The risk or severity of adverse effects can be increased when Ardeparin is combined with Tositumomab. Approved, Investigational Tranilast The risk or severity of bleeding can be increased when Tranilast is combined with Ardeparin. Approved, Investigational Trapidil Trapidil may increase the anticoagulant activities of Ardeparin. Approved Treprostinil Treprostinil may increase the anticoagulant activities of Ardeparin. Approved, Investigational Triamterene Ardeparin may increase the hyperkalemic activities of Triamterene. Approved Tribenoside Tribenoside may increase the anticoagulant activities of Ardeparin. Experimental Triflusal Triflusal may increase the anticoagulant activities of Ardeparin. Approved, Investigational Triptolide Triptolide may increase the anticoagulant activities of Ardeparin. Investigational Trolamine salicylate The risk or severity of bleeding can be increased when Trolamine salicylate is combined with Ardeparin. Approved Troxerutin Ardeparin may increase the anticoagulant activities of Troxerutin. Investigational Urokinase Urokinase may increase the anticoagulant activities of Ardeparin. Approved, Investigational, Withdrawn Valdecoxib Valdecoxib may increase the anticoagulant activities of Ardeparin. Approved, Investigational, Withdrawn Valsartan Ardeparin may increase the hyperkalemic activities of Valsartan. Approved, Investigational Venlafaxine Venlafaxine may increase the antiplatelet activities of Ardeparin. Approved Vitamin E Vitamin E may increase the anticoagulant activities of Ardeparin. Approved, Nutraceutical, Vet Approved Vorapaxar The risk or severity of adverse effects can be increased when Vorapaxar is combined with Ardeparin. Approved Warfarin Ardeparin may increase the anticoagulant activities of Warfarin. Approved Ximelagatran Ardeparin may increase the anticoagulant activities of Ximelagatran. Approved, Investigational, Withdrawn Zaltoprofen Zaltoprofen may increase the anticoagulant activities of Ardeparin. Approved, Investigational Zeranol Zeranol may decrease the anticoagulant activities of Ardeparin. Vet Approved Zileuton Zileuton may increase the anticoagulant activities of Ardeparin. Approved, Investigational, Withdrawn Zomepirac Zomepirac may increase the anticoagulant activities of Ardeparin. Withdrawn - Food Interactions
- Not Available
References
- General References
- Not Available
- External Links
- KEGG Drug
- D02980
- PubChem Substance
- 46505194
- Therapeutic Targets Database
- DAP000428
- PharmGKB
- PA164754878
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Ardeparin
- MSDS
- Download (65.5 KB)
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 1 Completed Basic Science Altered Heparin Response / Cardiopulmonary Bypass 1 2 Completed Prevention Venous Thromboembolism (VTE) 1 2 Terminated Prevention Thrombosis Prophylaxis (Risk of Thrombosis Due to Central Venous Line (CVL) 1 2 Withdrawn Treatment Diabetes, Diabetes Mellitus Type 1 1 3 Completed Prevention Cancers / Venous Thromboembolism (VTE) 1 3 Completed Prevention Venous Thromboembolism (VTE) 5 3 Completed Treatment Deep Vein Thrombosis (DVT) 1 3 Recruiting Prevention Catheter-Related Infections / Chronic Renal Failure (CRF) 1 3 Terminated Prevention Venous Thromboembolism (VTE) 1 4 Recruiting Treatment Infertilities 1 Not Available Recruiting Not Available Intra Operative Bleeding, Blood Salvage 1
Pharmacoeconomics
- Manufacturers
- Wyeth ayerst laboratories
- Packagers
- Not Available
- Dosage forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source water solubility Soluble Not Available - Predicted Properties
- Not Available
- Predicted ADMET features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
Taxonomy
- Classification
- Not classified
Targets
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Potentiator
- General Function
- Serine-type endopeptidase inhibitor activity
- Specific Function
- Most important serine protease inhibitor in plasma that regulates the blood coagulation cascade. AT-III inhibits thrombin, matriptase-3/TMPRSS7, as well as factors IXa, Xa and XIa. Its inhibitory a...
- Gene Name
- SERPINC1
- Uniprot ID
- P01008
- Uniprot Name
- Antithrombin-III
- Molecular Weight
- 52601.935 Da
References
- Mousa SA: The low molecular weight heparin, tinzaparin, in thrombosis and beyond. Cardiovasc Drug Rev. 2002 Fall;20(3):199-216. [PubMed:12397367]
- Lin P, Sinha U, Betz A: Antithrombin binding of low molecular weight heparins and inhibition of factor Xa. Biochim Biophys Acta. 2001 Apr 3;1526(1):105-13. [PubMed:11287128]
- Shaughnessy SG, Young E, Deschamps P, Hirsh J: The effects of low molecular weight and standard heparin on calcium loss from fetal rat calvaria. Blood. 1995 Aug 15;86(4):1368-73. [PubMed:7632944]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Agonist
- General Function
- Serine-type endopeptidase inhibitor activity
- Specific Function
- Thrombin inhibitor activated by the glycosaminoglycans, heparin or dermatan sulfate. In the presence of the latter, HC-II becomes the predominant thrombin inhibitor in place of antithrombin III (AT...
- Gene Name
- SERPIND1
- Uniprot ID
- P05546
- Uniprot Name
- Heparin cofactor 2
- Molecular Weight
- 57070.16 Da
References
- Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
- Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
- Mousa SA: The low molecular weight heparin, tinzaparin, in thrombosis and beyond. Cardiovasc Drug Rev. 2002 Fall;20(3):199-216. [PubMed:12397367]
- Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Drug created on June 13, 2005 07:24 / Updated on August 02, 2018 04:20